Quote from the full text:
Antimicrob Agents Chemother. 1996 Feb;40(2):468-9.Unlike azithromycin, which is rapidly cleared from the extracellular compartments, and beta-lactams, which do not effectively enter the intracellular compartment, clarithromycin has the ability to achieve and maintain bacteriocidal levels both intracellularly and extracellularly. Thus, it may act upon spirochetes in either compartment.
Clarithromycin in treatment of early Lyme disease: a pilot study.
Dattwyler RJ, Grunwaldt E, Luft BJ.
Lyme Disease Center, State University of New York at Stony Brook 11794-8161, USA.
Forty-one patients with erythema migrans were enrolled in an open-labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.
PMID: 8834900 [PubMed - indexed for MEDLINE]